Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Towa Aims To Restore Japanese Trust In Generics Quality

‘Future Of Generics Companies Are Worrisome’

Executive Summary

Japan’s Towa Pharmaceutical has published its fifth mid-term business plan, alongside financial results for the 12 months ended 31 March 2021.

You may also be interested in...



Sawai Lays Out Ten Year Goals Including ¥400bn In Revenues

Japan’s Sawai has laid out its mid- and long-term ambitions in a new company business plan, spanning both its local and overseas operations.

Rosemont Celebrates One Year Of Independence With 49% Growth

A year on from being spun-out of Perrigo and acquired by private equity, liquid generics specialist Rosemont Pharmaceuticals has revealed new details of the UK-based firm’s operations.

Catalent Joins Civica’s New Business Arm For Generic Manufacturing

CDMO Catalent and US health insurance giant Anthem have joined up with non-profit Civica’s new outpatient-focused generics business arm, CivicaScript, with plans to begin rolling out products as early as next year.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel